EPW
CORT icon

Evolve Private Wealth’s Corcept Therapeutics CORT Stock Holding History

Evolve Private Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+2,603
New +$157K 0.01% 879
2026
Q1 		– Sell
-10,304
Closed -$359K – 1008
2025
Q4 		$359K Buy
+10,304
New +$809K 0.02% 660

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolve Private Wealth's CORT Position: Q2 2026 in Review

Evolve Private Wealth opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,603 shares worth $226K. The stake represents 0.01% of the portfolio and ranks #879 among its holdings. This is a return to the name: Evolve Private Wealth previously reported a position in CORT as recently as Q4 2025.

Evolve Private Wealth first reported a position in CORT in Q4 2025 and has held it in 2 quarters since. The position peaked at $359K in Q4 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Evolve Private Wealth held 2,603 shares of Corcept Therapeutics worth $226K as of Q2 2026.
  • Corcept Therapeutics was a new Evolve Private Wealth position in Q2 2026.
  • Corcept Therapeutics made up 0.01% of Evolve Private Wealth's portfolio in Q2 2026, its #879 holding.
  • Evolve Private Wealth first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Evolve Private Wealth's Corcept Therapeutics position peaked at $359K in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.